Press Releases

Toronto, ON, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- In partnership with autistic people, caregivers, Autism Speaks Canada, Autism Alliance of Canada, the McMaster Autism Research Team, and with the participation of seventeen provincial, territorial, and other autism-focussed organizations, the 2023 Pandemic Canadian Autism Needs Assessment Survey was conducted to better understand the continuing impacts of the COVID-19 pandemic on autistic adults, caregivers, and... (continue reading...)

MIAMI, May 10, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing of nutritional supplements and foods, today announced its participation in Vitafoods Europe 2024, scheduled to take place in Geneva, Switzerland from May 14 to 16, 2024.

Vitafoods Europe is a premier event in the nutraceutical industry, typically... (continue reading...)

-  Vuzix will offer select clients a private look at its next generation optics system technologies designed specifically for fashion forward smart glasses

ROCHESTER, N.Y., May 10, 2024 /PRNewswire/ -- – Vuzix® Corporation (NASDAQ: VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses and Augmented Reality (AR) technology and products, announced it will be offering, by-request-only, demonstrations of its latest optical display system... (continue reading...)

Singapore, May 10, 2024 (GLOBE NEWSWIRE) -- In today's rapidly developing landscape of blockchain technology and digital currency payments, UPCX is at the forefront of optimizing payment systems and financial services. To maintain close ties with the community and transparently share upcoming product features and corporate milestones, UPCX will host an exclusive "Ask Me Anything" (AMA) live session on Twitter Spaces. This event, featuring UPCX's Chief Marketing... (continue reading...)

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open.

About Praxis  Praxis... (continue reading...)